Navigation Links
Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease

cals, Shire. "We are firmly committed to serving the needs of renal patients and ensuring that FOSRENOL is available to the prescribers and patients who can benefit from it."

In relation to the US, Shire continues to evaluate its options for securing a label extension to include CKD patients not on dialysis.

    Notes to Editors

    ABOUT FOSRENOL(R) (lanthanum carbonate)

    FOSRENOL is indicated:

    - In the EU as a phosphate binding agent for use in the control of
      hyperphosphataemia in chronic renal failure patients on haemodialysis
      or continuous ambulatory peritoneal dialysis. FOSRENOL is also
      indicated in adult patients with chronic kidney disease not on dialysis
      with serum phosphate levels greater than or equal to 1.78 mmol/L in
      whom a low phosphate diet alone is insufficient to control serum
      phosphate levels.(1)

    - In the US to reduce serum phosphate in patients with end stage renal

    - FOSRENOL is not available in all countries and prescribing information
      may differ between countries. Please consult your local prescribing

    - FOSRENOL works by binding to dietary phosphate in the GI tract; once
      bound, the lanthanum/phosphate complex cannot pass through the
      intestinal lining into the blood stream and is eliminated from the
      body.(1) As a consequence, overall phosphate absorption from the diet
      is decreased.

    - FOSRENOL is available in a broad range of dosage strengths including
      500mg, 750mg, and 1000mg tablets1 which facilitates an effective dosing
      regimen of one tablet per meal for the majority of patients.

    - FOSRENOL was first approved in Sweden in March 2004, and by the US FDA
      in October 2004. FOSRENOL was subsequently approved in all EU markets
      by the European Mutual Recognition Procedure and is now launched in 37
      markets worldwide. It continues to be approved and made availa
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. New CapSure™ Cleanroom Wiper from Berkshire Corporation Captures and Retains 42 Times More Contaminant Particles
2. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
3. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
4. Shire Initiates Two Adult ADHD Outreach Programs
5. Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
6. Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology
7. The Crohns & Colitis Foundation of America and Shire Launch Virtual IBD March on the Hill to Increase Funding for Digestive Disease Research
8. Shire begins the year with a strong performance
9. Shire plc: Results of the Annual General Meeting Held on April 28, 2009
10. Shire plc: First Quarter 2009 Results Date Notification - April 30, 2009
11. Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
Post Your Comments:
(Date:10/8/2015)... Oct. 8, 2015 Celemics, a global pioneer ... the North American market with the establishment of Celemics ... and Europe , has secured itself ... Enrichment methodology and sample preparation for DNA sequencing and ... hereditary and somatic genetic testing more accurately, quickly, and ...
(Date:10/8/2015)... 8, 2015 Global Biologics ... Biologics and Biosimilars industry . --> ... and Biosimilars Industry 2015 Deep Market Research Report, ... a professional and depth research report on ... ) , --> ) ...
(Date:10/8/2015)...  Today, DuPont and Caribou Biosciences, a leading ... announced a strategic alliance. As part of the ... portfolios, with DuPont receiving exclusive intellectual property rights ... and non-exclusive rights in other agricultural and industrial ... --> In addition, the alliance between ...
(Date:10/8/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... development of autologous cell therapies, today announced its schedule of ... in the month of October: Stem Cell ... will be presenting at the annual Partnering Forum, part ... be held October 7-9 in La Jolla, ...
Breaking Biology Technology:
... profile of Ranexa -, - Conference call ... PALO ALTO, Calif., Nov. 6 CV ... the U.S. Food and Drug,Administration (FDA) has approved ... tablets) for the treatment of,chronic angina. The new ...
... ALine increases microfabrication business development capabilities by hiring laboratory reagent ... ... (PRWEB) November 6, 2008 -- ALine, Inc., a high-tech provider ... Roger Anderson, PhD, as the Vice President of Operations. Dr. ...
... and Manufacturing Process Documentation for Customer ... ... Inc.,(OTC Bulletin Board: BLFS), a leading developer and marketer of ... today announced that it has submitted a Master File to ...
Cached Biology Technology:
(Date:9/28/2015)... YORK , Sept. 28, 2015  The ... respiration rate and body temperature, is an essential ... can be indicators of deterioration in a patient,s ... hospital, vital signs are typically taken during routine ... hours. If a patient deteriorates between these observation ...
(Date:9/24/2015)... NEW YORK , Sept. 24, 2015  EyeLock ... will be showcasing its award winning and latest technology ... Anaheim, California . EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA.   EyeLock,s platform uses video technology to deliver a ...
(Date:9/10/2015)... , Sept. 10, 2015 Pursuant Health ... Wellness to create an interactive, image-based health risk ... and wellness kiosk.  The unique assessment quantifies user ... number that suggests an individual,s biological age based ... as measured by the kiosk. Comprised ...
Breaking Biology News(10 mins):
... like houses, need building materials for their walls. And as ... at just the right moment to protect and allow the ... of the global Ludwig Institute for Cancer Research (LICR) has ... but has also conducted proof-of-principle studies that indicate taking away ...
... coloured males because they are easier to see and ... following her study of fish speciation in the East ... preference and eventually to speciation. , Evolutionary theory ... different characteristics in males. Yet females often pay attention ...
... word pollen to most people and it triggers thoughts of ... Alberta researcher has found an important spin-off for this fine ... from the Department of Biological Sciences at the U of ... pollen on boreal lakes. Rich in nutrients, pollen is an ...
Cached Biology News:
... Neogens enzyme-linked immunosorbent assay (ELISA) test ... screening devices for the detection of drugs ... kits are intended for forensic use only. ... be confirmed by a quantitative method such ...
96 Well Base Plate...
... is a recombinant human protein produced in E. ... pancreatic RNase A type enzymes. The mode ... RNases in a 1:1 ratio. The enzyme has ... tissues and cell types. Addition of the ribonuclease ...
Biology Products: